Drug Patents owned by Biogen Inc

1. Drug name - TECFIDERA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399514 BIOGEN INC Treatment for multiple sclerosis Feb, 2028

(5 years from now)

US10391160 BIOGEN INC Dimethyl fumarate and vaccination regimens Mar, 2035

(12 years from now)

US10994003 BIOGEN INC Dimethyl fumarate and vaccination regimens Mar, 2035

(12 years from now)

US10555993 BIOGEN INC Dimethyl fumarate and vaccination regimens Mar, 2035

(12 years from now)

US10959972 BIOGEN INC Methods of treating multiple sclerosis Nov, 2035

(13 years from now)

US11007167 BIOGEN INC Methods of treating multiple sclerosis Nov, 2035

(13 years from now)

US11007166 BIOGEN INC Methods of treating multiple sclerosis Nov, 2035

(13 years from now)

US11129806 BIOGEN INC Methods of treating multiple sclerosis Nov, 2035

(13 years from now)

Drugs and Companies using DIMETHYL FUMARATE ingredient

Treatment: Method of treating multiple sclerosis; Method of treating relapsing forms of multiple sclerosis before and after administering an inactive vaccine

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
120MG CAPSULE, DELAYED RELEASE;ORAL Prescription
240MG CAPSULE, DELAYED RELEASE;ORAL Prescription

2. Drug name - VUMERITY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8669281 BIOGEN INC Prodrugs of fumarates and their use in treating various diseases
Sep, 2033

(10 years from now)

US10080733 BIOGEN INC Prodrugs of fumarates and their use in treating various diseases
Sep, 2033

(10 years from now)

CN105452213B BIOGEN INC Fumaric Acid Ester Prodrugs And Their Use In The Treatment Of Various Diseases In The Application
Mar, 2034

(11 years from now)

CN105452213A BIOGEN INC Fumarate Prodrug And Application In Treating Multiple Disease
Mar, 2034

(11 years from now)

CN107501110A BIOGEN INC Ester Prodrugs And Their Use In The Treatment Of Various Diseases In The Application
Mar, 2034

(11 years from now)

CN107501110B BIOGEN INC Fumaric Acid Ester Prodrugs And The Use Thereof In The Treatment Of Various Diseases
Mar, 2034

(11 years from now)

EP2970101A4 BIOGEN INC Prodrugs Of Fumarates And Their Use In Treating Various Deseases
Mar, 2034

(11 years from now)

EP2970101A1 BIOGEN INC Prodrugs Of Fumarates And Their Use In Treating Various Deseases
Mar, 2034

(11 years from now)

EP2970101B1 BIOGEN INC Prodrugs Of Fumarates And Their Use In Treating Various Deseases
Mar, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9090558 BIOGEN INC Prodrugs of fumarates and their use in treating various diseases Sep, 2033

(10 years from now)

Drugs and Companies using DIROXIMEL FUMARATE ingredient

Treatment: Method of treating multiple sclerosis

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
231MG CAPSULE, DELAYED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.